The conference program for MEDICA 2013, International Trade Fair with Congress – World Forum for Medicine, is undergoing a full re-launch. The content repositioning for MEDICA 2013 (to be held from November 20 – 23, 2103 in Düsseldorf, Germany) is designed to closely fit the program of the trade fair’s topics relevant to medical equipment users and to expand the international side of the program.
BIOTRONIK has announced the European market launch of its Ilesto 7 Series today. Ilesto 7 is the world’s first DF4 ICD/CRT series approved for MRI, and includes one of the world’s smallest ICDs while also offering the greatest longevity—up to 11.5 years for the single chamber ICD.
CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that it has received conditional approval of its Investigational Device Exemption (IDE) for PerClot from the United States Food and Drug Administration (FDA).
Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the final results of the PUFs (Pipeline for Uncoilable or Failed Aneurysms) clinical study of its Pipeline™ embolization device have been published in the June issue of Radiology. Radiology is the official peer-reviewed medical journal of the Radiological Society of North America.
A more accurate and reliable stroke prediction model has been developed to help physicians decide whether to start blood-thinning treatment for patients with atrial fibrillation, as described in the current online issue of the Journal of the American Heart Association.
Sorin Group Announces First U.S. Implant of PARADYM RF SonR CRT-D for RESPOND CRT IDE Clinical TrialJune 20, 2013 10:00 am | by Business Wire | News | Comments
Sorin Group (MIL:SRN), a global medical device company and leader in the treatment of cardiovascular diseases, announces the first U.S. implant of its PARADYM SonR CRT System for the RESPOND CRT IDE Clinical Trial. Dr. B. A. Smith, Electrophysiologist, Piedmont Heart Institute, Atlanta, GA, performed the procedure on May 30.
Researchers at MIT’s Computer Science and Artificial Intelligence Laboratory have developed a new algorithm that can accurately measure the heart rates of people depicted in ordinary digital video by analyzing imperceptibly small head movements that accompany the rush of blood caused by the heart’s contractions.
Covidien (NYSE: COV), a leading global provider of healthcare products, has announced that an independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien’s Kendall SCD™ system with Vascular Refill Detection Technology on immobile stroke patients.
Systems such as a beating heart or a power grid that depend on the synchronized movement of their parts could fall prey to an invisible and chaotic tug-of-war known as a "chimera."
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, has obtained CE marking for REVIVE SE, a next-generation self-expanding clot removal device for use in treating acute ischemic stroke.
Systems such as a beating heart or a power grid that depend on the synchronized movement of their parts could fall prey to an invisible and chaotic tug-of-war known as a "chimera." A chimera state arises among identical, rhythmically moving components — known as oscillators — when a few of those parts spontaneously fall out of sync while the rest remain synchronized.
HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy TrialJune 17, 2013 8:50 am | by PR Newswire | News | Comments
HeartWare International has announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval to an IDE (Investigational Device Exemption) Supplement that allows HeartWare to commence enrollment in an additional patient cohort for ENDURANCE, the Company's pivotal, Destination Therapy clinical study.
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, has obtained CE marking for REVIVE SE, a next-generation self-expanding clot removal device for use in treating acute ischemic stroke, the company announced today at the Live Interventional Neuroradiology & Neurosurgery Course (LINNC) in Paris.
On this episode of The Pulse, rewired nerves from amputated limbs allow for prosthetic control with existing muscles, a bioengineered blood vessel is transplanted, diabetes is diagnosed through breath analysis alone, and a new technology is paving the way for low-cost electronic devices that work in direct contact with living tissue inside the body.
The consequences of high blood pressure are one of the most common causes of death worldwide. Despite this, according to the World Health Organization WHO, fewer than one in two of those affected measures their blood pressure regularly.
Micell Technologies, Inc. received CE (Conformite Europeenne) Mark approval for its MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) introducing a thin-strut stent that features elimination of the coating from the stent in 45-60 days and the complete absorption of the polymer coating within 90 days.
Approval Of Boston Scientific's Watchman Device Will Support Rapid Growth In The Global Heart Defect Closure Device MarketJune 12, 2013 8:00 am | by The Associated Press | News | Comments
According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the anticipated Food and Drug Administration (FDA) approval of Boston Scientific's WATCHMAN device will drive rapid growth in the market for global heart defect closure devices. ...
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval of its next-generation Ellipse™ and SJM Assura™ portfolio of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). The new devices are designed to lower the risk of lead abrasion and to ensure high-voltage therapy delivery.
Next-Generation Clot Retrieval Technology Improves Patient Outcomes vs. First- Generation Devices, Say Leading Stroke PhysiciansJune 11, 2013 11:59 am | by Covidien | News | Comments
Covidien brought together six of the world’s prominent thought-leaders in stroke at the 2013 European Stroke Conference. At a Covidien-sponsored symposium, the stroke experts presented and discussed data underscoring the benefits of endovascular therapy in treating acute ischemic stroke and, particularly, the important role that new devices play when this procedure is performed to remove blood clots from large vessels in the brain.
Wake Forest Baptist Medical Center doctors have found that using stress cardiac magnetic resonance (CMR) imaging in an Emergency Department observation unit to care for patients with acute chest pain is a win-win - for the patient and the institution.
Just a few years ago, integrated positron emission tomography and magnetic resonance (PET/MR) imaging was found only in research institutes, but little by little the technology has expanded into clinical practice. This is especially true for cardiac indications, for which the highly sensitive soft tissue contrast of MR and the functional and metabolic imaging of PET are particularly valuable.
Coronary artery disease (CAD) is one of the world’s most prevalent and silent killers. Positron emission tomography (PET), which images miniscule abnormalities in cellular metabolism, can tip off clinicians about cardiac disasters waiting to happen—including sudden death from a heart attack—better than standard angiography, researchers revealed at the Society of Nuclear Medicine and Molecular Imaging’s 2013 Annual Meeting.
Abbott Initiates Randomized Clinical Trial in Japan to Evaluate the AbsorbT Bioresorbable Vascular ScaffoldJune 11, 2013 9:30 am | by The Associated Press | News | Comments
Abbott (NYSE: ABT) today announced that it has initiated the ABSORB Japan randomized controlled clinical trial to evaluate the AbsorbT Bioresorbable Vascular Scaffold (BVS) in patients with coronary artery disease (CAD), the most common form of heart disease.
Teleflex Incorporated (NYSE:TFX), a leading global provider of medical devices for critical care and surgery, has announced it has received FDA 510(k) clearance to market its ARROW® NextStep® Retrograde Femoral Length Dialysis Catheters. Designed for clinician ease of insertion and sustained high flow rates, the ARROW NextStep Retrograde Femoral Length Catheters further strengthen the NextStep Hemodialysis Catheter portfolio.
Quallion, a leading developer and manufacturer of advanced lithium ion batteries, released test data demonstrating the potential to power long-term implantable medical devices. After 10 years of storage at an elevated temperature simulating conditions inside the human body, Quallion's cells showed minimal degradation in terms of calendar fade and self discharge.